thought you would like to read this--REAL HOPE OF A CURE

[Lani]

OPEN ACCESS: EDITORIAL: Whither HER2-Related Therapeutics?
[Journal of Clinical Oncology]
It is apparent that increasing knowledge of molecular signaling pathways regarding HER2/Neu amplified breast cancer biology has paved the way toward novel, innovative targeted combination therapeutics. The multiplicity of potential targets along the PI3K-AKT-mTOR or HER2-GRB7-RAC1 pathway requires careful preclinical evaluation to ensure optimal activity, minimal toxicity, and lack of resistance. The sheer multiplicity of approaches outlined above will need to correspond to measurements of driving molecular signaling pathways on an individual patient basis. In the meantime, the patient faces a panoply of HER2-directed therapies and state-of-the-art clinical trials, yielding better responses, survival, quality of life, and real hope of a cure.